Product Information
Fineron (Finerenone) 10mg is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist used to reduce the risk of kidney and cardiovascular complications in adults with Chronic Kidney Disease (CKD) associated with Type 2 Diabetes, and to treat chronic heart failure with mildly reduced or preserved ejection fraction. It works by blocking MR-mediated sodium reabsorption and MR overactivation in both the kidneys and the heart and blood vessels, a pathway thought to contribute to fibrosis and inflammation in these organs when overactive. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Fineron (Finerenone) 10mg
| Brand Name | Fineron (Finerenone) |
| Generic Name | Finerenone INN |
| Drug Class | Nonsteroidal, Selective Mineralocorticoid Receptor Antagonist (MRA) |
| Available Strength | 10mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 10 Tablets per Pack |
| Primary Indication | Chronic Kidney Disease Associated with Type 2 Diabetes, and Chronic Heart Failure (LVEF ≥40%) |
| Regulatory Approvals | USFDA Approved (CKD with T2D; also HFmrEF/HFpEF). EMA Approved (CKD with T2D; chronic heart failure, LVEF ≥40%). |
| Originator Brand | Kerendia by Bayer |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Fineron (Finerenone) Works
Fineron contains Finerenone, a nonsteroidal antagonist of the mineralocorticoid receptor (MR), a receptor activated by aldosterone and cortisol that regulates gene transcription related to sodium and fluid balance. When chronically overactivated, particularly in the context of diabetes and kidney disease, MR signalling is thought to contribute to fibrosis and inflammation in both epithelial tissue (such as the kidney) and non-epithelial tissue (such as the heart and blood vessels).
Finerenone blocks this MR-mediated sodium reabsorption and MR overactivation with high potency and selectivity. Unlike older, steroidal mineralocorticoid receptor antagonists, Finerenone has no relevant affinity for androgen, progesterone, oestrogen, or glucocorticoid receptors, which is thought to reduce the hormone-related side effects sometimes seen with earlier MRAs. By reducing MR overactivation, Fineron helps slow the progression of kidney damage and reduce cardiovascular strain in patients with CKD and type 2 diabetes, and improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction.
Fineron is taken as a once-daily oral tablet, with the starting dose determined by kidney function and adjusted over time based on blood potassium levels.
Indications for Fineron (Finerenone)
Fineron (Finerenone) is indicated for the following conditions:
|
Chronic Kidney Disease Associated with Type 2 Diabetes To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalisation for heart failure in adult patients with CKD associated with type 2 diabetes. |
|
Chronic Heart Failure with Mildly Reduced or Preserved Ejection Fraction For the treatment of symptomatic chronic heart failure with a left ventricular ejection fraction (LVEF) of 40% or greater in adults, to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits. |
Benefits of Fineron (Finerenone) 10mg
|
Dual Kidney and Heart Protection Fineron addresses both kidney and cardiovascular risk in patients with CKD and type 2 diabetes, a population who commonly face both types of complications together. |
Selective, Nonsteroidal Mechanism Fineron’s high selectivity for the mineralocorticoid receptor, without significant activity at other steroid hormone receptors, is designed to reduce the hormone-related side effects associated with older MRAs. |
Option for Preserved-Ejection-Fraction Heart Failure Fineron offers a treatment option for heart failure with mildly reduced or preserved ejection fraction, a form of heart failure with historically fewer proven treatment options than reduced-ejection-fraction disease. |
|
Affordable Alternative to Kerendia Fineron contains the same active ingredient as Kerendia by Bayer, at a significantly lower cost, making this therapy more financially accessible for long-term use. |
Convenient Once-Daily Dosing Fineron is taken as a single oral tablet once daily, with or without food, and can be crushed and mixed with water or soft food for patients who have difficulty swallowing whole tablets. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Fineron tablets. |
How to Take Fineron (Finerenone)
Route: Oral, with or without food, taken with a glass of water. Tablets should be swallowed whole; patients who cannot swallow whole tablets may crush the tablet and mix it with water or soft food, such as apple sauce, immediately before use.
Before starting treatment: Serum potassium and estimated glomerular filtration rate (eGFR) must be measured before starting Fineron. Treatment should not be started if serum potassium is above 5.0 mEq/L.
Starting dose (based on eGFR): eGFR 60 mL/min/1.73m² or above: start at 20mg (two 10mg tablets) once daily. eGFR 25 to under 60 mL/min/1.73m²: start at 10mg (one tablet) once daily. eGFR below 25 mL/min/1.73m²: Fineron is not recommended.
Target maintenance dose: 20mg once daily. Serum potassium should be measured about 4 weeks after starting or adjusting treatment, and the dose adjusted up or down based on the result, exactly as directed by the prescribing physician.
Missed dose: If a dose is missed, take it as soon as remembered on the same day; do not double up doses to make up for a missed one.
Hepatic impairment: Use with caution in patients with moderate or severe hepatic impairment; consult your physician for specific guidance.
Paediatric use: The safety and efficacy of Fineron in children and adolescents under 18 years have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Fineron treatment. Your physician will check serum potassium and eGFR before starting treatment, approximately 4 weeks after starting or after any dose adjustment, and periodically thereafter, particularly in patients at higher risk of hyperkalaemia. Monitoring also includes periodic blood pressure checks, since Fineron can modestly lower blood pressure. Report any muscle weakness, irregular heartbeat, unusual tiredness, tingling sensations, or dizziness to your doctor immediately, as these can be signs of elevated potassium or low blood pressure.
Drug Interactions and Important Information
Fineron is a major substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (such as itraconazole, ketoconazole, clarithromycin, or ritonavir) is contraindicated, as these can significantly increase Finerenone exposure and hyperkalaemia risk. Avoid moderate CYP3A4 inhibitors where possible; if unavoidable, more frequent potassium monitoring is advised. Avoid strong CYP3A4 inducers, as these may reduce Finerenone’s effectiveness. Do not take Fineron with grapefruit or grapefruit juice.
Use caution when combining Fineron with other medicines that can raise blood potassium levels, including potassium-sparing diuretics, other mineralocorticoid receptor antagonists, or potassium supplements, due to an increased risk of hyperkalaemia. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Fineron.
Side Effects and Precautions
|
Common Side Effects Hyperkalaemia (elevated blood potassium) Hypotension (low blood pressure) Hyponatraemia (low blood sodium) Dizziness or light-headedness |
Serious Warnings and Precautions Severe hyperkalaemia, which can cause dangerous heart rhythm disturbances if not monitored and managed. Contraindicated in patients with adrenal insufficiency. Limited pregnancy data; animal studies suggest possible developmental toxicity at high exposures. |
Who Should Use Fineron (Finerenone)?
Fineron is suitable for adult patients with Chronic Kidney Disease associated with type 2 diabetes, particularly those at risk of disease progression or cardiovascular complications, and adult patients with chronic heart failure with mildly reduced or preserved ejection fraction (LVEF 40% or above). It is prescribed by nephrologists, cardiologists, and endocrinologists managing these conditions. A thorough medical assessment including baseline serum potassium, eGFR, and blood pressure is required before initiating treatment, with adrenal function considered in patients where insufficiency is suspected.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Fineron under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Fineron is one of Everest’s specialty nephrology products, offering a bioequivalent alternative to Kerendia by Bayer at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty medications. We ensure Fineron (Finerenone) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Fineron (Finerenone) from Mediaid Pharmacy?
Fineron represents a modern, targeted approach to protecting the kidneys and heart in patients with diabetes-related kidney disease and certain forms of heart failure. As the generic equivalent of Kerendia by Bayer, it delivers the same active ingredient, Finerenone, with the same proven, selective mineralocorticoid receptor antagonism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Fineron gives patients worldwide access to effective, evidence-based nephrology and cardiology therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Finerenone option with worldwide delivery, Fineron from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Fineron (Finerenone)
What is Fineron (Finerenone) used for?
Fineron (Finerenone) is used to reduce the risk of kidney and cardiovascular complications in adults with Chronic Kidney Disease associated with type 2 diabetes, and to treat chronic heart failure with a left ventricular ejection fraction of 40% or above. It works by blocking overactive mineralocorticoid receptor signalling that contributes to kidney and heart damage.
How should I take Fineron (Finerenone)?
Fineron is taken orally, once daily, with or without food. Your starting dose (10mg or 20mg) depends on your kidney function (eGFR), and is adjusted based on a blood potassium test taken about 4 weeks after starting or changing the dose. Always follow your physician’s exact instructions and attend all scheduled blood tests.
What strength is Fineron available in?
Fineron is available in a 10mg tablet, supplied in a pack of 10 tablets. Higher doses, such as the 20mg target maintenance dose, are achieved by taking two tablets together, exactly as prescribed by your physician.
Is Fineron the same as Kerendia (Finerenone by Bayer)?
Yes. Fineron is the generic equivalent of Kerendia. Both contain the same active ingredient, Finerenone, and work through the same selective mineralocorticoid receptor antagonism. Fineron is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism as Kerendia at a significantly lower cost.
What are the side effects of Fineron (Finerenone)?
The most common side effects are elevated blood potassium (hyperkalaemia), low blood pressure, low blood sodium, and dizziness. Hyperkalaemia is the most clinically important risk and is why regular blood tests are required. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.
Can Fineron be used with other medications?
Fineron must not be combined with strong CYP3A4 inhibitors, and caution is needed with other medicines that raise blood potassium, including potassium-sparing diuretics and potassium supplements. Avoid grapefruit and grapefruit juice during treatment. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Fineron.
Is Fineron (Finerenone) safe during pregnancy or breastfeeding?
Data on Fineron use during pregnancy and breastfeeding are limited. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding, so that the potential risks and benefits can be discussed for your individual situation.
Can I order Fineron (Finerenone) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Fineron (Finerenone) 10mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Fineron (Finerenone) 10mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com













